

INDEX

- ACP Journal Club* 139, 140
ACT UP 63
Acupuncture 13
Adherence *See*
 Compliance/adherence
Advertisement 39, 83–85, 86, 87,
 136
Agency for Health Care Policy and
 Research AHCPR 150
Agouron 83–84
American College of Physicians ACP
 140
Antibiotics 47, 82
Antimicrobial Therapy, Inc. 87
Appadurai, A. 162
Aristotle 126, 130
Atkinson, P. 57, 70, 134, 137
Attitude
 Attitude and disease progression
 45–46, 133, 164
 Patient/physician attitude in health
 care 55, 63, 66, 74, 75, 89–95,
 97, 103, 107, 122, 146, 156
Australia 74, 82, 144
Authority
 Authority of senior physicians 135
 Medical authority 52, 71, 149
 Physician authority 52, 54, 65,
 67–70, 71, 148
Autonomy
 Patient autonomy 23, 52, 54, 66–
 67, 82, 96, 164, 165
 Physician autonomy 2, 68, 119,
 132, 149–51, 168
AZT (brand name Retrovir) 26, 90
Bayer, R. 22, 52
Beisecker, A. E. 55, 71
Benoist, J. xvii, 57
Biography 19
 Biographical disruption 20, 21, 24
 Biographical time 29, 25–32
 Patient biography 18, 122
 Physician biography 21, 118, 135
Body
 Definitions of the body 19
 Mind/body dualism 57, 164
 The body and medication 70, 81–
 83, 164
 The body in medicine 3, 43, 55,
 58, 65, 122
 The infected body 16, 20, 32, 38,
 42, 44, 48–49
Boehringer-Ingelheim 29
Bourdieu, P. 135, 162
Brazil 155
Bristol-Myers Squibb 29

- Brunner, H. H. 119, 150, 151
 Bucher, H. C. 133, 136
 Bury, M. 20
 Canada 126, 155
 Cancer 27, 30
 Cao, Y. 33
 Carricaburu, D. 5, 24
 Cassell, E. J. 21, 57
 Chemokines 37, 42
 Chesney, M. A. 98
 Chronic sickness 18, 20, 26–30, 53, 111
 Clifford, J. 4, 161, 162
 Clinical anthropology xiv
 Clinical epidemiology 128, 135
 Clinical gaze 55, 65, 122
 Clinical moratorium 107
 Clinical trials 54, 76, 103, 105, 125, 126, 136, 138, 151, 160, 167
 Cochrane Collaboration 139
Cochrane Library 139
 Cochrane, A. 139
 Cohen, J. 37
 Competence 68, 112, 121, 127, 128, 130, 146, 151, 156, 166
 Complementary therapies 13, 60–62
 Complementary therapists 142
 Compliance/adherence xvii, 63, 70, 97–103, 121, 136, 165, 168
 Conceptions of self 19
 Conrad, P. xviii, 54, 98
 Consumerism 53, 55, 63, 71
 Control
 Control over the infection 17, 23, 24, 45, 69, 98, 164
 Control over treatment 95
 Control within medicine 118
 External control over medicine 147–56, 165, 167
 Cook-book medicine 131
 Corbin, J. 18
 Crawford, R. 16, 22, 23, 48, 164
 Dannecker, M. 52
 Death xv, 26, 30–32, 134
 DelVecchio Good, M.-J. 30, 33, 107, 118, 135, 146, 149, 158, 160
 Developing countries 29
 Diabetes 21, 26
 Diet 19, 46
 DiGiacomo, S. M. 4, 102
 Doctor-patient interaction xvii, 52, 59, 61, 64, 66–71, 91, 111, 113, 121, 141, 149, 165
 Douglas, M. 17
 Drug lag 104
 Drug use 17, 23, 25, 48
 Drug use and compliance/adherence 99, 101–3
 Duesberg, G. H. 34
 Eddy, D. M. 140, 153
 Egger, M. xv
 Embodiment 20, 23, 42
 Eradication 26, 34–38
 Ethnography xiii, 157–63, 168
 Evidence-Based Medicine 151–56, 166–68
 Definition 125
Evidence-Based Medicine (journal) 139, 140

- Exceptionalism 52
- Explanatory models xvii
- Fauci, A. S. 49
- Fee, E. 26
- Feinberg, M. B. 37, 106, 107, 112, 114
- Feldman, J. L. 38, 63, 102
- Field xiii, 2, 159, 161, 162
- Fieldwork 2
- Flexibility 42, 46, 111
- Food and Drug Administration FDA 104
- Foucault, M. 55, 65, 99, 118, 163, 167
- Fox, R. C. 107, 137, 145
- France 63, 74, 77, 101, 102, 119
- Fujimura, J. H. xvii, 33
- Further education 139, 141–45
- Gaines, A. D. 55
- Gallo, R. 28
- Germany 77, 155
- Giddens, A. 19, 137
- Gilman, S. 17
- GlaxoWellcome* 29
- Good, B. J. 4, 5, 25, 58, 68
- Gordon, D. 125–26, 155
- Great Britain 77, 82, 111, 120, 161
- Guidelines xviii, 70, 71, 76, 124, 136, 145, 149–50, 154, 165, 166
 - Definitions and types of guidelines 140
 - Evidence-based guidelines 127, 140, 166
 - Swiss HIV treatment guidelines 78, 94, 97, 106, 114, 121
 - United States HIV treatment guidelines 97, 106, 107, 114
 - Use of guidelines by Swiss physicians 141
- Gupta, A. xiii, 161, 162
- Hahn, R. A. 133
- Haraway, D. 39, 42–43, 46, 48
- Hausarztmodell* 66
- Health 16
- Helman, C. G. 22, 46, 164
- Herdt, G. 26
- Hess, D. J. xv, 158
- HIV test xiii, 21, 25, 164
- Ho, D. D. 33–38, 74
- Homeopathy 13, 82
- Homosexuality 17, 24
- Hunt, L. M. 164
- Hypertension 21, 26
- Illich, I. 47
- Illness-disease dichotomy 55–58
- Immune system 42–44, 49, 82, 163
- Immunology 32, 37, 42, 47
- Indinavir (brand name Crixivan) 104
- Insurance companies 71, 104, 150, 165
- Internet 87, 139, 141–43, 148, 160, 161
- Interviews, semi-structured 2–4
- Japan xvi, 86
- Kaufert, P. 107, 137
- Kaufman, S. R. 52, 70
- Kitahata, M. M. 112
- Kleinman, A. xvii, 54, 57, 68
- Knowledge
 - Access to knowledge 87, 111, 135

- Adaptation of knowledge 131
- Hierarchy of knowledge 118
- Knowledge vs. belief 48, 56, 145
- Power/knowledge *See* Power
- Production of knowledge 42, 105, 138, 145
- Transfer of knowledge 124, 128, 140, 143, 158, 160
- Types of knowledge 124, 125, 133–38, 151, 153, 167
- Koenig, B. A. 36, 96, 103, 157
- Lancet, The (journal)* 148
- Latour, B. 158
- Lee, B. 37, 42
- Levy, J. A. 37
- Lifestyle 45–46, 53, 164
- Lock, M. 23, 57, 164
- Long-term survival 2, 31, 32
- Managed care 113
- Marcus, G. E. 55, 158, 161
- Martin, E. 42–44, 46, 47, 48, 82, 131, 158–59
- Mattingly, C. 3, 48
- McMaster Medical School 126, 128
- Medical anthropology xvii, 57, 68, 70
- Medical discourse xiv
- Medical sociology 57, 70
- Merck Sharpe & Dome* 29
- Meta-analysis 127, 139, 143, 152, 166
- Montagnier, L. 28
- Multi-sited ethnography 158
- Narrative xiii, 3, 4–5, 20, 129
- Nature (journal)* 28, 34, 86
- Naylor, C. D. 146
- Nelfinavir (brand name Viracept) 83
- Netherlands, The 30, 76, 78, 115
- New England Journal of Medicine, The* 33
- Non-progression 32, 133
- Normalization 52
- Oppenheimer, G. M. 22, 37
- Pantaleo, G. 33
- Parson, T. 53
- Patent 28, 30, 86
- Patent and Trademark Amendment Act 86
- Patient-centered medicine 55, 95
- Patton, C. 42
- Payer, L. 38, 77
- Perelson, A. S. 35
- Perrin, L. 26
- Personal identity 16, 19, 23, 24–25, 81
- Pharmaceutical companies 30, 42, 83–87, 98, 103–4, 136, 138, 158, 164
- Pollution 16–17, 81
- Power
 - Definitions of power 55, 99, 163
 - Power of medication 70, 86, 104, 164
 - Power relations between GPs and specialists 67–70, 166
 - Power relations between physicians and patients xiv, 52, 53, 58, 70, 96, 143, 148, 166
 - Power relations in medical science 33, 42

- Power relations in medicine xiii, 2, 51, 135, 150, 149–53, 163, 165
- Power/knowledge 96, 120, 155, 167
- Practice standards 149
- Pratt, M. L. xiii, 129
- Prevention 47, 52, 53
- Preventive medicine 42, 53
- Probabilistic thinking 137
- Protease inhibitors xv, 26, 34, 83
- Public health 30, 51, 93
- Questionnaire survey 6–7
- Rabinow, P. 86
- Radley, A. 54
- Reeder, L. G. 53
- Responsibility
 - Responsibility for health and sickness 22–24, 25, 164, 168
 - Responsibility in health care 54, 95, 97, 99, 122, 164–65
- Retrovirus Study Group 28
- Risk 44, 53, 137, 152
- Risk groups 101
- Rite of passage xiv
- Roche 29, 83–85
- Rouse, J. xvii, 34, 86
- Estroff 17, 29
- Sackett, D. L. xix, 99, 102, 125, 126–30, 132, 134, 136, 157, 166
- Sanford Guide to HIV/AIDS Therapy* 87
- Saquinavir (brand names Invirase and Fortovase) 84
- Scheper-Hughes, N. 20, 164
- Schizophrenia 17, 29
- Science 34–37, 42, 48, 56, 58, 124–34, 152, 156, 158, 167, 168
- Science (journal)* 28, 86
- Self-control 22, 24, 25, 99, 100, 164
- Shared care 111, 113, 116–17, 121
- Shilling, C. 19
- Side effects 37, 82, 83, 96, 105
- Silverman, D. 55, 95, 122
- Singer, M. xiv
- Socrates 154
- South Africa 30
- Spiegel, Der (magazine)* 30
- State 71, 99, 104, 149
- Stigma 16–18, 22, 23, 30, 164
- Stimson, G. V. 98
- Swiss Federal Office of Public Health SFOPH 45, 74, 141–44
- Swiss HIV Cohort Study SHCS xvi, 7, 62, 76, 103
- Swiss Medical Association FMH 119, 150, 151
- Swiss National Science Foundation 150
- Systematic reviews 127, 139, 143, 166
- TarMed 119, 150
- Taussig, M. T. 21, 56
- Thailand 30
- Time 19
- Time (magazine)* 34, 35
- Total Quality Management 131
- Treichler, P. A. xv, 26, 55
- TRIPS agreements 30
- Trostle, J. A. 97–99

The New Era of AIDS

HIV and Medicine in Times of Transition

Kopp, C.

2002, XX, 188 p., Hardcover

ISBN: 978-1-4020-1048-4